Articles

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer. Read More ›

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma. Read More ›

Results from the ARROW study show that pralsetinib demonstrates broad and durable antitumor activity across multiple advanced solid tumor types, regardless of RET fusion genotype. Read More ›

Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue. Read More ›

The AcceleRET Lung study will evaluate the efficacy and safety of pralsetinib compared with standard of care for first-line treatment of patients with advanced/metastatic RET fusion–positive non–small-cell lung cancer. Read More ›

Results from the phase 2 GEOMETRY mono-1 study confirm capmatinib to be efficacious in second-line treatment of patients with MET exon 14–mutated non–small-cell lung cancer. Read More ›

An updated analysis of 3 phase 1/2 trials finds that entrectinib continues to demonstrate clinically meaningful responses in patients with NTRK fusion–positive solid tumors, including those with and without baseline central nervous system disease. Read More ›

The next-generation RET inhibitor TPX-0046 demonstrates potent in vitro and in vivo activity against a diverse range of RET alterations, including solvent front mutation–mediated resistance. Read More ›

Selpercatinib (LOXO-292) use was associated with durable antitumor activity in patients with RET-mutant medullary thyroid cancer previously treated with cabozantinib and/or vandetanib as well as in cabozantinib/vandetanib-naïve patients. Read More ›

In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time. Read More ›